XML 80 R73.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information - Schedule of Segment Reporting Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Segment Reporting Information [Line Items]          
Revenues $ 26,771 $ 25,225 $ 48,829 $ 52,397  
Cost of revenues 1,151 770 2,045 1,749  
Gross profit 25,620 24,455 46,784 50,648  
Operating expenses excluding cost of revenues:          
Selling and marketing 15,194 14,414 26,035 26,956  
Research and development 3,425 3,355 6,520 5,537  
General and administrative 4,829 3,424 9,784 6,822  
Loss on disposal of assets, net 1 68 1 68  
Total operating expenses excluding cost of revenues 23,449 21,261 42,340 39,383  
Income (loss) from operations 2,171 3,194 4,444 11,265  
Other (expense) income, net (145) (72) (38) 50  
Change in fair value of warrant liability 212 2,913 2,467 7,201  
Income tax expense (662) (1,497) (1,563) (4,043)  
Net income 1,576 4,538 5,310 14,473  
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 906 16 1,413 27  
Total assets 152,646   152,646   $ 125,406
Purchase of property and equipment     378 1,687  
Cost of revenue          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 47   47    
Selling and marketing          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 29   29    
General and administrative          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 830 16 1,337 27  
Gyre Pharmaceuticals          
Segment Reporting Information [Line Items]          
Revenues 26,771 25,225 48,829 52,397  
Cost of revenues 1,151 770 2,045 1,749  
Gross profit 25,620 24,455 46,784 50,648  
Operating expenses excluding cost of revenues:          
Selling and marketing 15,194 14,414 26,035 26,956  
Research and development 3,337 3,077 6,366 5,086  
General and administrative 2,857 2,549 6,413 4,806  
Loss on disposal of assets, net 1 68 1 68  
Total operating expenses excluding cost of revenues 21,389 20,108 38,815 36,916  
Income (loss) from operations 4,231 4,347 7,969 13,732  
Other (expense) income, net (237) 53 (175) 115  
Income tax expense (662) (1,497) (1,563) (4,043)  
Net income 3,332 2,903 6,231 9,804  
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 349   427    
Total assets 121,142   121,142   114,248
Purchase of property and equipment     378 1,673  
Gyre Pharmaceuticals | Cost of revenue          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 47   47    
Gyre Pharmaceuticals | Selling and marketing          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation     29    
Gyre Pharmaceuticals | General and administrative          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 273   351    
Gyre          
Operating expenses excluding cost of revenues:          
Research and development 88 278 154 451  
General and administrative 1,970 874 3,366 2,015  
Total operating expenses excluding cost of revenues 2,058 1,152 3,520 2,466  
Income (loss) from operations (2,058) (1,152) (3,520) (2,466)  
Other (expense) income, net 92 (125) 137 (65)  
Change in fair value of warrant liability 212 2,913 2,467 7,201  
Net income (1,754) 1,636 (916) 4,670  
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 557 16 986 27  
Total assets 31,139   31,139   10,790
Purchase of property and equipment       14  
Gyre | General and administrative          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 557 16 986 27  
Other          
Operating expenses excluding cost of revenues:          
General and administrative 2 1 5 1  
Total operating expenses excluding cost of revenues 2 1 5 1  
Income (loss) from operations (2) (1) (5) (1)  
Net income (2) $ (1) (5) $ (1)  
Supplemental disclosure of stock-based compensation expense:          
Total assets $ 365   $ 365   $ 368